Insulet (NASDAQ:PODD)‘s stock had its “outperform” rating reiterated by investment analysts at Leerink Swann in a research note issued to investors on Thursday, January 3rd, The Fly reports. They currently have a $100.00 target price on the medical instruments supplier’s stock, down from their previous target price of $110.00. Leerink Swann’s price objective indicates a potential upside of 36.89% from the company’s previous close. Leerink Swann also issued estimates for Insulet’s Q2 2019 earnings at $0.18 EPS, Q3 2020 earnings at $0.24 EPS, Q4 2020 earnings at $0.24 EPS and FY2023 earnings at $2.95 EPS.
A number of other research analysts also recently issued reports on PODD. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 11th. Zacks Investment Research upgraded shares of Insulet from a “hold” rating to a “buy” rating and set a $119.00 target price on the stock in a research report on Monday, October 1st. Morgan Stanley upped their price target on Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. Oppenheimer set a $100.00 price target on Insulet and gave the company a “hold” rating in a research note on Friday, November 2nd. Finally, UBS Group assumed coverage on Insulet in a research note on Tuesday, November 27th. They issued a “buy” rating and a $105.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $99.87.
PODD opened at $73.05 on Thursday. The stock has a market capitalization of $4.42 billion, a PE ratio of -158.80 and a beta of 1.56. The company has a debt-to-equity ratio of 2.95, a quick ratio of 3.99 and a current ratio of 4.58. Insulet has a twelve month low of $70.80 and a twelve month high of $108.90.
Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The business had revenue of $151.10 million for the quarter, compared to the consensus estimate of $148.82 million. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) EPS. Analysts expect that Insulet will post -0.05 earnings per share for the current year.
In other Insulet news, SVP David Colleran sold 6,113 shares of the firm’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $80.41, for a total transaction of $491,546.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Shacey Petrovic sold 1,134 shares of the firm’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $86.91, for a total value of $98,555.94. The disclosure for this sale can be found here. In the last three months, insiders sold 7,849 shares of company stock valued at $638,509. 3.60% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. SNS Financial Group LLC bought a new position in Insulet in the third quarter valued at about $225,000. CIBC Asset Management Inc acquired a new stake in shares of Insulet during the third quarter valued at about $227,000. AMP Capital Investors Ltd acquired a new stake in shares of Insulet during the second quarter valued at about $274,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Insulet during the second quarter valued at about $275,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Insulet during the second quarter valued at about $300,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Featured Article: What is the Quick Ratio?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.